Amidst a major transformation in the pharmaceutical industry driven by stricter technical barriers from the amended Law on Pharmacy, Traphaco Joint Stock Company (Ticker: TRA) has announced an optimistic business roadmap for 2026.
Key highlights of the company’s strategy and operational performance include:
-
2026 Financial Plan: The company aims for a revenue of 2,916 billion VND and a post-tax profit of 306 billion VND. This target represents a 10% growth compared to the previous year, continuing the momentum from 2025 (when profit reached 278 billion VND, an 8% increase).
-
Distribution System Restructuring: Traphaco executed a strategic move by streamlining 26 second-tier branches into 3 primary branches. The establishment of a specialized distribution entity has optimized resources and enhanced control over the OTC channel, which accounts for 89% of total revenue.
-
Breakthroughs in New Segments: The past year saw exponential growth in the e-commerce channel (tripling) and premium product lines. High-end herbal medicine grew by 68%, while modern medicine saw a 31% increase.
-
Investing in Core Values: Research and Development (R&D) remains the long-term focus. Traphaco successfully launched 18 new products and completed bioequivalence (BE) testing for various generic drugs to strengthen its position in medical tenders.
Ms. Dao Thuy Ha, CEO of Traphaco, emphasized that focusing on scientific profiles and standardized herbal cultivation areas according to international GACP-WHO standards is the foundation for adapting to modern consumers’ increasing demands for safety and origin transparency.